Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2021 | Promising clinical trials in CBI: ENVIS-ion study

Thomas Meinel, MD, Bern University Hospital, and University of Bern, Bern, Switzerland, shares promising ongoing clinical trials focusing on covert brain infarction (CBI). Dr Meinel highlights the sub-analysis of the ASPREE study, the ENVIS-ion study, assessing whether patients with CBI at baseline might be a subgroup benefiting from acetylsalicylic acid therapy. Although the overall ASPREE trial was negative, there is clear evidence that CBI patients are high-risk vascular patients and could potentially benefit from acetylsalicylic acid. Other studies looking at atrial fibrillation detection rate with implantable cardiac monitors to investigate whether rhythm monitoring should be performed in patients with incidentally discovered CBI are also highly awaited. This interview took place during the European Academy of Neurology 2021 congress.

Disclosures

The Swiss National Science Foundation (Grant number 32003B_189077) supports a multicentre study on the incidence of silent atrial fibrillation in patients with covert brain infarction, led by our group.